Nigeria Looks to Simple Packaging Controls and International Cooperation to Curb Counterfeit Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nigeria Looks to Simple Packaging Controls and International Cooperation to Curb Counterfeit Drugs


ePT--the Electronic Newsletter of Pharmaceutical Technology

The distribution of counterfeit drugs is a serious problem in Nigeria, as in many developing nations, driven by the desire of an impoverished population for drugs at the lowest possible price. A recent video report from CNN highlights Nigeria’s response to this problem, which includes vigilant police work, and a novel strategy for easily identifying legitimate products adopted by some Nigerian manufacturers:  

The strategy is the innovation of the Boston-based company Sproxil, and relies on a code contained on a scratch card within the drug packaging. Consumers can enter the code by phone and receive instant confirmation that the product is legitimate.  Manufacturers pay for the service and have been able to recapture market share from the counterfeit market. In CNN’s video, Dr. Ashifi Gogo, CEO of Sproxil states: “In a sense, the counterfeiters are paying for this service, which puts a smile on everyone’s face, except the counterfeiters.”

In addition to local solutions, Nigeria is reaching out to its trade partners to help combat this problem. On Mar. 16, 2011, a Memorandum of Understanding in the field of pharmaceuticals was signed between Nigeria’s Department of Pharmaceuticals and India’s National Agency for Food and Drug Administration and Control. Among other things, the document outlines policies that will help promote mutual trade in good quality drugs, drug testing and analysis, and detection and prevention of the supply of adulterated, fake, drugs. The agreement stipulates a stiff penalty ¾ life imprisonment ¾ for Indians caught producing or distributing counterfeit pharmaceuticals in Nigeria, as well as confiscation of property by the government.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here